Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial

• Autores principales: Luis Puig (Autor), Antonio Costanzo (Autor), Elke M. G. J. de Jong (Autor), Tiago Torres (Autor), Richard B. Warren (Autor), Robert Wapenaar (Autor), Sven Wegner (Autor), Patricia Gorecki (Autor), Talia Gramiccia (Autor), Maria Jazra (Autor), Jozefien Buyze (Autor), Curdin Conrad (Autor)
• Formato: Libro
• Publicado: Adis, Springer Healthcare, 2024-08-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract Introduction The interleukin-23p19 subunit inhibitor, guselkumab, has demonstrated improvements in clinical and patient-reported outcome (PRO) measures in patients with moderate-to-severe psoriasis. Understanding the relationship among clinical response, PRO measures and baseline characteri...